[
  {
    "criterion": "Mentions the importance of seeking a specialist or a multidisciplinary team for advanced disease management.",
    "axis": "completeness",
    "point": 5
  },
  {
    "criterion": "States that WHO Group 1 PAH is the most common classification in scleroderma patients.",
    "axis": "accuracy",
    "point": 5
  },
  {
    "criterion": "Provides information on the ESC guidelines for evaluating scleroderma-associated PAH.",
    "axis": "completeness",
    "point": 8
  },
  {
    "criterion": "Does not address the user's request for more information on management strategies or follow-up testing guidelines.",
    "axis": "instruction_following",
    "point": -3
  },
  {
    "criterion": "Provides a brief summary of the WHO groupings for pulmonary hypertension in scleroderma patients.",
    "axis": "communication_quality",
    "point": 5
  },
  {
    "criterion": "Does not consider left heart disease as a potential cause of PH in scleroderma patients.",
    "axis": "accuracy",
    "point": -4
  },
  {
    "criterion": "Asks the user if they would like more information on management strategies or follow-up testing guidelines.",
    "axis": "context_awareness",
    "point": 5
  },
  {
    "criterion": "Does not provide any information on the role of biomarkers (BNP/NT-proBNP) in the diagnosis of scleroderma-associated PAH.",
    "axis": "completeness",
    "point": -6
  },
  {
    "criterion": "States that pulmonary function tests are useful for quantifying concurrent interstitial lung disease.",
    "axis": "accuracy",
    "point": 5
  },
  {
    "criterion": "Does not address the potential for scleroderma patients to have combined issues with Group 1 PAH and interstitial lung disease.",
    "axis": "completeness",
    "point": -4
  },
  {
    "criterion": "Provides a clear and concise summary of the classification of pulmonary hypertension in scleroderma patients.",
    "axis": "communication_quality",
    "point": 8
  },
  {
    "criterion": "Does not consider the role of cardiac or pulmonary causes in the development of PH in scleroderma patients.",
    "axis": "accuracy",
    "point": -6
  },
  {
    "criterion": "Mentions the importance of right heart catheterization (RHC) in confirming hemodynamics.",
    "axis": "completeness",
    "point": 5
  },
  {
    "criterion": "States that the ESC guidelines outline a comprehensive approach for evaluating scleroderma-associated PAH.",
    "axis": "accuracy",
    "point": 5
  },
  {
    "criterion": "Does not provide any information on the role of functional testing (6MWT) in the diagnosis of scleroderma-associated PAH.",
    "axis": "completeness",
    "point": -6
  },
  {
    "criterion": "Provides a clear and concise summary of the WHO groupings for pulmonary hypertension in scleroderma patients.",
    "axis": "communication_quality",
    "point": 8
  },
  {
    "criterion": "Does not consider the role of imaging in the diagnosis of scleroderma-associated PAH.",
    "axis": "accuracy",
    "point": -4
  }
]